| P2093 | author name string | Chen Hu | |
| | Feng Yu | |
| | De-Zai Dai | |
| | Yin Dai | |
| | Khan Hussien Hamed | |
| P2860 | cites work | Cardiac ryanodine receptor phosphorylation by CaM Kinase II: keeping the balance right | Q24315563 |
| | Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death | Q24674590 |
| | Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database | Q28199862 |
| | Catecholaminergic polymorphic ventricular tachycardia | Q28287523 |
| | Dissociation of FKBP12.6 from ryanodine receptor type 2 is regulated by cyclic ADP-ribose but not beta-adrenergic stimulation in mouse cardiomyocytes | Q28512354 |
| | Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia | Q33155477 |
| | Redox regulation, NF-kappaB, and atrial fibrillation. | Q33644314 |
| | Catecholaminergic polymorphic ventricular tachycardia: recent mechanistic insights | Q34557909 |
| | Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome | Q34764296 |
| | Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome | Q34800033 |
| | Molecular determinants of altered contractility in heart failure | Q35791489 |
| | Calstabin deficiency, ryanodine receptors, and sudden cardiac death | Q35874314 |
| | What causes sudden death in heart failure? | Q35919160 |
| | Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure | Q35921523 |
| | Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. | Q36466847 |
| | Acute beta-adrenergic overload produces myocyte damage through calcium leakage from the ryanodine receptor 2 but spares cardiac stem cells | Q36513042 |
| | Ryanodine receptor phosphorylation at Serine 2030, 2808 and 2814 in rat cardiomyocytes. | Q36968487 |
| | Sarcoplasmic reticulum calcium leak and cardiac arrhythmias | Q36979482 |
| | Crosstalk between L-type Ca2+ channels and the sarcoplasmic reticulum: alterations during cardiac remodelling | Q37002238 |
| | The sarcoplasmic reticulum and arrhythmogenic calcium release | Q37002270 |
| | Molecular aspects of the congenital and acquired Long QT Syndrome: clinical implications | Q37108947 |
| | NADPH oxidase contributes to coronary endothelial dysfunction in the failing heart | Q37138926 |
| | Protein kinase C in heart failure: a therapeutic target? | Q37176180 |
| | Mitochondrial oscillations in physiology and pathophysiology. | Q37265452 |
| | Ryanodine receptor and calsequestrin in arrhythmogenesis: what we have learnt from genetic diseases and transgenic mice | Q37332464 |
| | Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach | Q37359189 |
| | Redox modification of ryanodine receptors contributes to sarcoplasmic reticulum Ca2+ leak in chronic heart failure. | Q40928544 |
| | Models of torsades de pointes: effects of FPL64176, DPI201106, dofetilide, and chromanol 293B in isolated rabbit and guinea pig hearts. | Q45970514 |
| | Dofetilide enhances the contractility of rat ventricular myocytes via augmentation of Na+-Ca 2+ exchange | Q46119975 |
| | The role of amlodipine in the treatment of chronic heart failure in women | Q46764006 |
| | Calcium antagonist property of CPU228, a dofetilide derivative, contributes to its low incidence of torsades de pointes in rabbits | Q46984748 |
| | Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die? | Q50894485 |
| | Abrupt changes in FKBP12.6 and SERCA2a expression contribute to sudden occurrence of ventricular fibrillation on reperfusion and are prevented by CPU86017. | Q53552559 |
| | Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in mice | Q79915411 |
| | Right-ventricular failure is associated with increased mitochondrial complex II activity and production of reactive oxygen species | Q80507848 |
| | Ryanodine receptor: a novel therapeutic target in heart disease | Q80551254 |
| | If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed? | Q81212513 |
| | Use of a failing rabbit heart as a model to predict torsadogenicity | Q83894597 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 77-83 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | Journal of Pharmacy and Pharmacology | Q10532762 |
| P1476 | title | CPU228, a derivative of dofetilide, relieves cardiac dysfunction by normalizing FKBP12.6, NADPH oxidase and protein kinase C epsilon in the myocardium | |
| | CPU228, a derivative of dofetilide, relieves cardiac dysfunction by normalizing FKBP12.6, NADPH oxidase and protein kinase C ε in the myocardium | |
| P478 | volume | 62 | |